LDDD: AI 评分 51/100 — AI 分析 (4月 2026)

Longduoduo Company Limited provides preventive healthcare solutions in China, focusing on cardiovascular and cerebrovascular diseases. The company offers a range of services, including disease screening, healthcare treatments, and products through third-party providers and sales agents.

Key Facts: AI Score: 51/100 Sector: Healthcare

公司概况

概要：

Longduoduo Company Limited delivers preventive healthcare solutions in China, addressing cardiovascular and cerebrovascular diseases. Their services encompass disease screening, treatments, and healthcare products distributed via third-party channels. Operating in the diagnostics and research segment, the company caters to a growing demand for preventive care in the Chinese market.

LDDD是做什么的？

Founded in 2020 and headquartered in Hohhot, China, Longduoduo Company Limited operates within the preventive healthcare sector, focusing on solutions for cardiovascular and cerebrovascular diseases. The company's inception was driven by the increasing prevalence of these conditions in China and the growing demand for proactive healthcare measures. Longduoduo offers a suite of preventive healthcare services, including disease screening, healthcare treatments, and healthcare products. These services are designed to mitigate the risks associated with myocardial infarction, cerebral infarction, hemiplegia, and other related conditions. The company utilizes a network of third-party healthcare service providers, product suppliers, and sales agents to deliver its offerings to the market. Longduoduo's service portfolio includes specialized treatments such as meridian-regulating and consciousness restoring iatrotechnics, double blood purification, immunological ozonated autohemotherapy, platelet-rich plasma, relaxation therapy, vegetative nerve regulation, and microwave therapy. These diverse therapeutic approaches aim to provide comprehensive preventive care to its clientele. While a relatively young company, Longduoduo is strategically positioned to capitalize on the expanding healthcare market in China, driven by increasing health awareness and government initiatives promoting preventive care.

LDDD的投资论点是什么？

Longduoduo Company Limited presents a speculative investment opportunity within the Chinese preventive healthcare market. The company's focus on cardiovascular and cerebrovascular disease prevention aligns with growing health concerns and government support for proactive healthcare measures. However, the company's negative P/E ratio of -51.82 and negative profit margin of -10.9% indicate financial challenges. The high gross margin of 98.5% suggests potential for profitability if operational efficiencies improve. Key growth catalysts include expanding service offerings and penetrating new geographic regions within China. Investors should carefully consider the risks associated with investing in a small-cap OTC-listed company with limited financial history.

LDDD在哪个行业运营？

Longduoduo Company Limited operates in the growing Chinese healthcare market, specifically within the preventive healthcare segment. The demand for preventive care is increasing due to rising healthcare awareness and government initiatives promoting early disease detection and management. The market is competitive, with established players and emerging companies offering various preventive healthcare solutions. Longduoduo differentiates itself through its specialized treatments and focus on cardiovascular and cerebrovascular diseases. The company's success depends on its ability to effectively market its services, establish strong partnerships, and maintain high-quality standards.

Medical - Diagnostics & Research

Healthcare

LDDD有哪些增长机遇？

Expansion into New Geographic Regions: Longduoduo can expand its services to other regions within China, targeting areas with high prevalence of cardiovascular and cerebrovascular diseases. The Chinese healthcare market is vast, offering significant growth potential for companies that can effectively penetrate new regions. This expansion could involve establishing new partnerships with local healthcare providers and sales agents. Timeline: Ongoing.
Development of New Preventive Healthcare Products: Longduoduo can invest in research and development to create new preventive healthcare products that complement its existing service offerings. These products could include dietary supplements, medical devices, or digital health solutions. The market for preventive healthcare products is growing rapidly, driven by increasing consumer awareness and demand for proactive health management. Timeline: Ongoing.
Strategic Partnerships with Hospitals and Clinics: Forming strategic partnerships with hospitals and clinics can provide Longduoduo with access to a wider patient base and enhance its credibility. These partnerships can involve offering Longduoduo's services within the hospital or clinic setting, or co-developing new preventive healthcare programs. The hospital and clinic market in China is large and fragmented, offering numerous partnership opportunities. Timeline: Ongoing.
Leveraging Telemedicine and Digital Health Platforms: Longduoduo can leverage telemedicine and digital health platforms to expand its reach and improve patient engagement. This can involve offering online consultations, remote monitoring, and personalized health coaching. The digital health market in China is growing rapidly, driven by increasing internet penetration and the adoption of mobile health technologies. Timeline: Ongoing.
Focus on Personalized Healthcare Solutions: Tailoring preventive healthcare solutions to individual patient needs can improve outcomes and enhance patient satisfaction. This can involve using genetic testing, lifestyle assessments, and other data to develop personalized treatment plans. The market for personalized healthcare is growing, driven by advances in genomics and data analytics. Timeline: Ongoing.

Market capitalization of $0.02 billion indicates a small-cap company with potential for high growth but also higher risk.
Negative P/E ratio of -51.82 reflects current unprofitability, requiring careful monitoring of future earnings.
High gross margin of 98.5% suggests strong pricing power or a focus on high-value services.
Beta of 1.53 indicates higher volatility compared to the overall market.
No dividend yield reflects a focus on reinvesting earnings for growth.

LDDD提供哪些产品和服务？

Provides disease screening services for early detection of health risks.
Offers healthcare treatments focused on preventing cardiovascular and cerebrovascular diseases.
Distributes healthcare products designed to promote overall wellness and disease prevention.
Delivers meridian-regulating and consciousness restoring iatrotechnics.
Offers double blood purification services.
Provides immunological ozonated autohemotherapy.
Administers platelet-rich plasma therapy.
Offers relaxation therapy, vegetative nerve regulation, and microwave therapy.

LDDD如何赚钱？

Generates revenue through the provision of preventive healthcare services.
Sells healthcare products through third-party distributors and sales agents.
Partners with healthcare providers to offer services within their facilities.
Focuses on preventing myocardial infarction, cerebral infarction, hemiplegia, and cardiovascular and cerebrovascular diseases.

Individuals seeking preventive healthcare solutions in China.
Patients at risk of cardiovascular and cerebrovascular diseases.
Healthcare providers who partner with Longduoduo to offer preventive services.
Consumers interested in purchasing healthcare products for disease prevention.

Specialized treatment offerings like meridian-regulating iatrotechnics and double blood purification.
Focus on the specific market of cardiovascular and cerebrovascular disease prevention in China.
Established network of third-party healthcare service providers and sales agents.
Proprietary healthcare products and treatment protocols.

什么因素可能推动LDDD股价上涨？

Upcoming: Potential partnerships with hospitals and clinics to expand service reach.
Ongoing: Expansion of service offerings to include new preventive healthcare treatments.
Ongoing: Development and launch of new healthcare products.
Ongoing: Leveraging telemedicine and digital health platforms to improve patient engagement.

LDDD的主要风险是什么？

Potential: Intense competition from established healthcare providers in China.
Potential: Changes in government regulations and healthcare policies could impact the company's operations.
Potential: Economic slowdown in China could reduce demand for preventive healthcare services.
Ongoing: Limited financial disclosure increases investment risk.
Ongoing: Low trading volume and liquidity can lead to price volatility.

LDDD的核心优势是什么？

Specialized focus on cardiovascular and cerebrovascular disease prevention.
Comprehensive range of preventive healthcare services and products.
Established network of third-party healthcare providers and sales agents.
Innovative treatment offerings such as meridian-regulating iatrotechnics.

LDDD的劣势是什么？

Limited operating history as the company was founded in 2020.
Negative P/E ratio and profit margin indicate financial challenges.
Small market capitalization and OTC listing increase investment risk.
Dependence on third-party providers and sales agents.

LDDD有哪些机遇？

Expansion into new geographic regions within China.
Development of new preventive healthcare products and services.
Strategic partnerships with hospitals and clinics.
Leveraging telemedicine and digital health platforms.

LDDD面临哪些威胁？

Intense competition from established healthcare providers.
Changes in government regulations and healthcare policies.
Economic slowdown in China.
Potential for product liability claims.

LDDD的竞争对手是谁？

Concord Medical Services Holdings Limited — Offers a broader range of cancer treatment services. — (CVKD)
Harvard Bioscience, Inc. — Focuses on tools and technologies for life science research. — (HBIO)
P3 Health Partners Inc. — Operates a network of primary care providers. — (PIII)
Propel BioSciences, Inc. — Specializes in products for neuroscience research. — (PRPO)
Vicarious Surgical Inc. — Develops surgical robots. — (RBOT)

Key Metrics

MoonshotScore: 51/100

Company Profile

CEO: Hongxiao Zhou
Headquarters: Hohhot, CN
Employees: 52
Founded: 2023

AI Insight

AI analysis pending for LDDD

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Longduoduo Company Limited do?

Longduoduo Company Limited is a preventive healthcare solutions provider based in China, focusing on cardiovascular and cerebrovascular diseases. The company offers a range of services, including disease screening, healthcare treatments, and healthcare products, delivered through third-party healthcare service providers, product suppliers, and sales agents. Their specialized treatments include meridian-regulating iatrotechnics, double blood purification, and immunological ozonated autohemotherapy, targeting the prevention of serious conditions like myocardial infarction and cerebral infarction.

What do analysts say about LDDD stock?

As of March 15, 2026, there is no available analyst coverage for Longduoduo Company Limited (LDDD) due to its small market capitalization and OTC listing. Key valuation metrics such as P/E ratio (-51.82) and profit margin (-10.9%) indicate current unprofitability. Investors should conduct their own thorough research and consider the risks associated with investing in a small-cap OTC-listed company before making any investment decisions. The high gross margin of 98.5% is a positive indicator, but needs to be balanced against the other financial metrics.

What are the main risks for LDDD?

The main risks for Longduoduo Company Limited include intense competition from established healthcare providers in China, potential changes in government regulations and healthcare policies, and the risk of an economic slowdown in China affecting demand for preventive healthcare services. Additionally, the company's limited financial disclosure and OTC listing increase investment risk due to lower regulatory oversight and potential for price volatility. Investors should carefully consider these risks before investing in LDDD.